Anti-VEGF-A Humanized Antibody

Anti-VEGF-A Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar antibody is a recombinant humanized IgG1 kappa monoclonal without an Fc fragment. This antibody binds to the receptor-binding site of vascular endothelial growth factor A (VEGF-A) and inhibits binding with its receptors (VEGFR1 and VEGFR2). This prevents VEGF-mediated proliferation and migration of endothelial cells and angiogenesis. The original drug received FDA approval in 2006 for the treatment of wet age-related macular degeneration. The drug has also been approved to treat macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Immunogen Sequence:Human VEGF-A

Target Alternative Name:rhuFab V2, Fab-12 variant Y0317, RhuFab, vascular endothelial growth factor A, VEGFA

Species Reactivities:Human

Tag Line:The research-grade biosimilar antibody binds to and inhibits vascular endothelial growth factor A (VEGF-A) and thus inhibits angiogenesis. The original drug received FDA approval to treat wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:In vitro

Positive Control:/

Application And Usages:In vitro studies

Handling:The antibody solution should be gently mixed before use.